top of page
Supported projects
Naya Therapeutics
Clinical-stage biotech developing two next-generation modalities—astate-211 radiopharmaceuticals and NK cell-engaging bifunctional antibodies—for hepatocellular carcinoma and multiple myeloma.
PSCC's entrance
Décembre 2025
Localization
USA - Florida
Modality
targeted alpha-therapy and bispecific Ab
Development status
Biotech - Phase 1b
Lauréat (s)
bottom of page